Adamis Completes Acquisition of Prostate Drug Candidates

Adamis Pharmaceuticals Corporation Tuesday announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer.
Earth Times